🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million instances each year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the extremely scarce treatment choices currently available.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The global health body has classified it as a "critical concern". A tracking program revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on findings released by a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines an injection and a pill. The research enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have voiced optimism. The availability of a one-pill regimen like this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.